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Lysosomal storage diseases (LSDs) are often caused
by mutations compromising lysosomal enzyme
folding in the endoplasmic reticulum (ER), leading
to degradation and loss of function. Mass spectrom-
etry analysis of Gaucher fibroblasts treated with
mechanistically distinct molecules that increase
LSD enzyme folding, trafficking, and function re-
sulted in the identification of nine commonly downre-
gulated and two jointly upregulated proteins, which
we hypothesized would be critical proteostasis
network components for ameliorating loss-of-func-
tion diseases. LIMP-2 and FK506 binding protein 10
(FKBP10) were validated as such herein. Increased
FKBP10 levels accelerated mutant glucocerebro-
sidase degradation over folding and trafficking,
whereas decreased ER FKBP10 concentration led
to more LSD enzyme partitioning into the calnexin
profolding pathway, enhancing folding and activity
to levels thought to ameliorate LSDs. Thus, targeting
FKBP10 appears to be a heretofore unrecognized
therapeutic strategy to ameliorate LSDs.
INTRODUCTION
The secreted eukaryotic proteome is folded in the endoplasmic
reticulum (ER) (Brodsky and Skach, 2011), wherein folded
proteins such as N-glycosylated lysosomal enzymes engage
their trafficking receptors, triggering vesicular packaging for
transport to the Golgi and on to the lysosome (Brodsky and
Skach, 2011; Edmunds, 2010; Futerman and van Meer, 2004;
Hebert et al., 2010; Mazzulli et al., 2011; Reczek et al., 2007;
Sun et al., 2010; Vembar and Brodsky, 2008; Vitner et al.,
2010). Excessive misfolding and degradation of a mutant lyso-
somal enzyme results in a deficiency of lysosomal enzyme
activity leading to substrate accumulation in several cell types,
which manifests in a lysosomal storage disease (LSD) (Futerman
and van Meer, 2004; Sun et al., 2010; Vitner et al., 2010; Zhao
and Grabowski, 2002). The delicate balance between LSD
enzyme folding, trafficking, and function versus degradationChemistry & Biology 20, 4(Miyata et al., 2011) is achieved by the ER proteostasis network
comprising > 75 proteins (Adachi et al., 2008; Lee et al., 2003;
Okada et al., 2002; Yamamoto et al., 2007).
Treating LSD patient-derived fibroblasts, e.g., Gaucher fibro-
blasts, with either of two mechanistically distinct proteostasis
regulators (PRs), molecules that enhance proteostasis network
capacity without eliciting cytotoxicity at the levels used herein,
led to more efficient folding and trafficking of several mutant
misfolding-prone lysosomal enzymes, increasing their lysosomal
activity (Mu et al., 2008a, 2008b; Ong et al., 2010). The first
mechanistic class of PRs, which includes MG-132, activates
the unfolded protein response (UPR) (Mu et al., 2008b) stress-
responsive signaling pathway that transcriptionally remodels
the ER by upregulating ER chaperones (Chen et al., 2011; Hartl
et al., 2011) and degradation components, while also attenuating
translation and expanding the ER (Ron and Walter, 2007;
Schro¨der and Kaufman, 2005). While MG-132 is a proteasome
inhibitor and induces additional stress-responsive signaling,
we established that UPR activation is sufficient to account for
MG-1320s PR function (Mu et al., 2008b). The second mecha-
nistic category of PRs, exemplified by the drug diltiazem, post-
translationally enhances ER folding capacity at the expense of
ER-associated degradation (ERAD) (Brodsky and Skach, 2011;
Hebert et al., 2010) by increasing the ER Ca2+ concentration,
likely enhancing the chaperoning activity of a subset of Ca2+-
dependent chaperones including calnexin, which is critical for
the folding of glucocerebrosidase (GC), the lysosomal enzyme
associated with Gaucher disease, and other N-glycosylated
lysosomal enzymes (Mu et al., 2008a; Ong et al., 2010). Pro-
teomic analyses of Gaucher fibroblasts treated with these com-
pounds identified FK506 binding protein 10 (FKBP10), which
when depleted, decreased the degradation of mutant GC,
increasing its folding, trafficking, and lysosomal function.
Depletion of FKBP10 also increased the lysosomal activity of
a-mannosidase, suggesting that targeting FKBP10 may be
a general therapeutic strategy for ameliorating LSDs.
RESULTS
Comparative Proteomics Identifies Additional GC ER
Proteostasis Network Components
Herein, we employed mass spectrometry, namely multidimen-
sional protein identification technology (MudPIT), to compare03–415, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 403
Figure 1. Comparative Proteomics Identified Additional GC Proteostasis Network Components
(A) A Venn diagram showing the proteins that were significantly upregulated or downregulated byMG-132 or diltiazem in L444PGCfibroblasts. See also Table S1.
(B) Proteins that appeared in bothMG-132- or diltiazem-treated fibroblasts are sorted into four categories, namely synthesis, folding, trafficking and degradation.
See also Table S2.
(C and D) Diltiazem and MG-132 are mechanistically distinct and combining the two PRs synergistically increases GC activity (C) and the mature GC glycoform
(D). Quantification of endo H resistant and sensitive GC bands is shown on the right of (D).The experiments were done three times. The data in (C) are reported as
mean ± SEM (n = 8) and any statistical significance was calculated using a two-tailed Student’s t test. *p < 0.01.
See also Figure S1.
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harboring the L444P GC mutation treated with MG-132
(0.8 mM, 3 days) or diltiazem (10 mM, 5 days), the PRs described
above (Mu et al., 2008a, 2008b; Ong et al., 2010). Cellular
proteins whose levels were either significantly up- or downregu-
lated by PR treatment were identified using the spectral counting
method (Figure 1A; Table S1 available online) (Eng et al., 1994;
Liao et al., 2007; Liu et al., 2004; Rikova et al., 2007; Washburn
et al., 2001). A protein of interest was defined as one that had
to be detected in both pharmacologically-treated and vehicle-
treated fibroblast lysates (at least two peptides per protein).
The concentration of the majority of the fibroblast proteome404 Chemistry & Biology 20, 403–415, March 21, 2013 ª2013 Elseviewas unaltered by MG-132 or diltiazem treatment (Figure S1A),
suggesting that most proteins were folding efficiently (Powers
et al., 2009) and thus their concentration was not significantly
altered by proteostasis network modulation.
Notably, the majority of proteins modulated by diltiazem treat-
ment were not altered by MG-132 application and vice versa,
confirming their largely distinct PR functions (Figures 1A and
1B). Oppositely up- or downregulated proteostasis network
components included those involved in (1) protein synthesis,
(2) folding (Bukau et al., 2006; Deuerling and Bukau, 2004;
Tang et al., 2008), (3) trafficking (Gu¨rkan et al., 2006), and
(4) degradation (Vembar and Brodsky, 2008) (Table S2). Thatr Ltd All rights reserved
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was further supported by the 4.3-fold increase in L444P GC
intact cell activity achieved by their co-application to fibroblasts,
a slight synergistic effect (Figure 1C, *p < 0.01). The endoglyco-
sidase H (endo H)-resistant GC band, representing the popula-
tion of GC that had properly folded, exited the ER and trafficked
at least through the Golgi compartment, was significantly
increased upon diltiazem and MG-132 co-application (Fig-
ure 1D), and the GC transcript level was increased by 2.5 fold
(Figure S1B), presumably owing to MG-132 treatment because
diltiazem did not alter the GC mRNA level.
However, there were a few proteins that were either commonly
upregulated (two proteins) or downregulated (nine proteins)
upon treatment with MG-132 or diltiazem (Figure 1A). Of these
11 proteins, we followed up on FKBP10, a jointly downregu-
lated candidate not previously associated with LSD enzyme
proteostasis (Figure 1A), and LIMP-2 (also called SCARB2),
a previously identified GC proteostasis network component
(Reczek et al., 2007) that was commonly upregulated.
Validating LIMP-2 as an Important GC Proteostasis
Network Component
Consistent with the previously reported role of LIMP-2 as a GC
trafficking receptor (Reczek et al., 2007), LIMP-2 siRNA adminis-
tration (>90% knockdown, Figure S2) decreased GC activity by
3.3-fold in WT GC fibroblasts (Figure 2A, left), by 2.2-fold in
N370S GC fibroblasts (Figure 2A, right), and by 2.2-fold in
L444P GC fibroblasts (Figure 2B, vehicle control) relative to the
nontargeting (NT) siRNA control. Moreover, co-application of
LIMP-2 siRNA with either diltiazem or MG-132 in L444P GC
fibroblasts substantially reduced the increase in L444P GC
activity that was afforded by PR treatment (Figure 2B). Silencing
LIMP-2 also decreased the endo H resistant GC band intensity
(Figure 2C, *p < 0.05).
In contrast, transient overexpression of LIMP-2 in L444P GC
fibroblasts increased the endoH resistant post-ERGCglycoform
(Figure 2D) and its lysosomal trafficking as detected by indirect
immunofluorescence (Figure 2E), indicating enhanced ER exit
and lysosomal trafficking. These data confirm the prior report
of the importance of LIMP-2 in GC trafficking (Reczek et al.,
2007), and indicate that LIMP-2 is likely a limiting proteostasis
network component for ER-to-Golgi-to-lysosomeGC trafficking.
A Decreased ER FKBP10 Concentration Enhances
Lysosomal Enzyme Proteostasis
We next turned our attention to the ER FKBP10 protein,
harboring four peptidylprolyl cis-trans isomerase (PPIase)
domains and two C-terminal Ca2+-binding EF hand domains
(Figure 3A). There are at least five FKBPs in the ER, and some
of them (e.g., FKBP10, FKBP2 [or FKBP13] and FKBP7
[or FKBP23]) have been proposed to act as molecular chaper-
ones or cochaperones (Feng et al., 2011; Ishikawa et al.,
2008). FKBP10 (and possibly the highly homologous protein
FKBP9) has been shown to inhibit the aggregation of denatured
citrate synthase and rhodanese, suggesting that it may be a
holdase chaperone (Ishikawa et al., 2008). Perhaps the most
convincing evidence that FKBP10 may be a chaperone is that
mutations in FKBP10 cause collagen misfolding diseases
(Alanay et al., 2010; Kelley et al., 2011; Shaheen et al., 2011;Chemistry & Biology 20, 4Venturi et al., 2012) and delay type I collagen fibril formation
in vitro. The best understood FKBP protein, not in the FKBP9/
10 family, is trigger factor, a ribosome-associated cytosolic
chaperone that is clearly a holdase and a PPIase (Deuerling
and Bukau, 2004; Stoller et al., 1995). Given the redundancy in
ER PPIases, one would expect that not all of them function solely
as PPIases (Jakob et al., 2009; Kang et al., 2008). We set out to
test the hypothesis that FKBP10 could influence the ER LSD
enzyme degradation versus folding decision, not a previously
proposed role for FKBP10, but one that is consistent with the
notion that PPIases can bind to proteins undergoing folding
(Ishikawa et al., 2008).
FKBP10 levels were reduced 2-fold in either diltiazem- or
MG-132-treated L444P GC fibroblasts (Table S1 and Fig-
ure S3A). The concentration of other FKBP family members
was also suppressed by the application of these PRs (Table S2
and Figure 1B). FKBP10 mRNA levels in L444P GC fibroblasts
decreased when treated with diltiazem (reduced 1.4-fold) or
MG-132 (reduced 3-fold) or both (reduced 3-fold) versus vehicle
(Figure S3B), indicating that FKBP10 is primarily transcriptionally
downregulated. It is also established that FKBP10 is directed
toward ERAD in fibroblasts in response to ER stress, known to
result from MG-132 treatment (Murphy et al., 2011).
SiRNA silencing of FKBP10 in L444P GC fibroblasts (>70%
knockdown, Figure S3C) resulted in a 1.4-fold increase in GC
activity (18% of WT GC activity) versus the NT siRNA control
(Figure 3B, left, *p < 0.01). While this increasemay seemmodest,
it is thought to be sufficient to ameliorate Gaucher disease
(Schueler et al., 2004). FKBP9 was not detected by MudPIT,
but the similarity of its domain architecture with FKBP10 (Fig-
ure 3A) and its ER localization led us to also explore its potential
role in lysosomal enzyme proteostasis. siRNA silencing of
FKBP9 (>70% knockdown, Figure S3C) increased cellular
L444P GC activity 1.4-fold (Figure 3B, left, *p < 0.01). In contrast,
silencing FKBP2, harboring only one PPIase domain (Figure 3A),
did not alter L444P GC activity (Figure 3B, left). Silencing
FKBP10 (>60% knockdown, Figure S3D) increased the activity
of the Gaucher G202R mutant 2.0-fold (Figure 3B, middle, *p <
0.01). Silencing FKBP10 or FKBP9 (>60% knockdown, Fig-
ure S3E) also increasedWT GC activity 1.3-fold (Figure 3B, right,
*p < 0.01). Indirect immunofluorescence microscopy studies
revealed that knockdown of FKBP10 or FKBP9 dramatically
increased the ability to detect cellular L444P GC, normally
almost completely degraded by ERAD (Figure 3C; cf. green fluo-
rescence in left panels), and importantly, partially restored GC
lysosomal colocalization, artificially colored white (Figure 3C;
right panels). Moreover, knockdown of FKBP9 or FKBP10
increased the endo H resistant post-ER GC glycoform concen-
trations in L444P andWTGC fibroblasts (Figure 3D). Conversely,
overexpressing FLAG-tagged FKBP10 (Figure S3F) decreased
both WT and L444P GC activity by 20% in patient-derived
fibroblasts (Figure 3E, *p < 0.01).
We measured the mRNA levels of GC and several established
UPR markers (spliced XBP1, CHOP, and BiP), as well as the
protein levels of several established UPR markers (p-eIF2a,
BiP and HRD1) and verified that FKBP10 depletion did not
alter GC mRNA abundance or induce the UPR (Figures
S3G and S3H). Nor did knockdown of FKBP10 (or FKBP9
and FKBP10) significantly alter L444P GC fibroblast viability03–415, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 405
Figure 2. LIMP-2 Is an Important GC Proteostasis Network Trafficking Component
(A) The knockdown of LIMP-2 significantly decreases the WT and N370S GC activity in the fibroblasts when compared to the NT siRNA control.
(B and C) Silencing LIMP-2 diminishes the increase in L444P GC activity (B) and the endo H resistant post-ER GC glycoform in western blot analysis (C) that is
afforded by either MG-132 or diltiazem alone. Quantification of endo H-resistant GC bands is shown at the bottom of (C).
(D and E) The modest transient overexpression of LIMP-2 in L444P GC fibroblasts increases the endo H-resistant post-ER GC glycoform in western blot analysis
(D) and the lysosomal trafficking of L444P GC in indirect immunofluorescence study (E). Quantification of endo H-resistant GC bands and LIMP-2 bands is shown
on the right of (D).The experiments were done three times.
The data in (A)–(D) are reported as mean ± SEM (n = 8 for A and B) and any statistical significance was calculated using a two-tailed Student’s t test. *p < 0.05.
See also Figure S2.
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FKBP knockdown) with tunicamycin or thapsigargin to induce
ER proteome misfolding/aggregation did not significantly exac-
erbate proteotoxicity. However, there was a consistent trend
toward decreased cell viability upon UPR activation when both
FKBP9 and FKBP10 were downregulated (Figure S3I, cf. left
and right panels).406 Chemistry & Biology 20, 403–415, March 21, 2013 ª2013 ElsevieAn Endogenous GC-FKBP10 Interaction in the ER
We detected a GC-FKBP10 endogenous interaction in immuno-
precipitates ofGCanalyzed bywestern blot from the ER fractions
of HeLa cells and WT GC fibroblasts (Figure 3F). Coomassie
blue staining showed two strong bands between 50 kDa and
75 kDa in the GC immunoprecipitate of HeLa ER fractions (Fig-
ure 3F). In-gel digestion and tandem MS analysis revealed thatr Ltd All rights reserved
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bottom band contained GC. The unique peptides identified are
listed in Figure 3F. Collectively, these results demonstrated
that decreasing FKBP9 or FKBP10 levels in the ER enhanced
mutant GC proteostasis in patient-derived fibroblasts through
a direct interaction and without any involvement of an UPR.
FKBP10 Binds to Misfolding-Prone GC Directing
it to ERAD
For mechanistic investigations, we used an overexpression
system, focusing on FKBP10, since FKBP10 and FKBP9 appear
to be structurally and functionally equivalent. Co-overexpression
of FKBP10 together with GC decreased the steady state levels of
VSVG-WT and -L444P GC (Figure 4A, input), not due to UPR
induction (Figure S4A). Immunoprecipitating overexpressed
WT or L444P VSVG-tagged GC from HeLa lysate showed that
they bound similarly to glycosylated overexpressed FLAG-
tagged FKBP10 (Figure 4A). Inhibiting proteasomal degradation
using lactacystin led to more endogenous WT GC binding to
overexpressed FKBP10 (Figure 4B), consistent with the hypoth-
esis that FKBP10 is partitioning GC to ERAD. p53 was used as
a control because it is degraded by the proteasome (Maki
et al., 1996).
We hypothesized that FKBP10 enhancesmutant GC degrada-
tion in fibroblasts and HeLa cells by binding to more misfolding-
prone mutant GC and directing more of it to ERAD by a pathway
that is distinct from the calnexin-EDEM1 ERAD pathway. Over-
expressed EDEM1 (an acceptor of misfolded glycoproteins
released from calnexin) (Molinari et al., 2003; Oda et al., 2003)
bound to WT and L444P GC and decreased the GC steady state
levels (Figure 4A, input). However, reducing the level of EDEM1
(Figures S4B and S4C) or ER a-mannosidase I (required for
ERAD of terminally misfolded glycoproteins) (Figure S4D), or
inhibiting the latter (Figure S4E) did not enhance L444P GC pro-
teostasis in fibroblasts. Inhibiting ER a-mannosidase I noticeably
increased the endo H sensitive GC glycoform, indicating ER
accumulation of L444P GC without productive ER folding and
export (Figures S4D and S4E).
FKBP10’s Function inGCProteostasis DoesNot Require
Its PPIase Activity or Ca2+ Binding
We investigated whether the PPIase activities of human FKBP10
affected its ability to influence GC proteostasis. Treatment with
FK506, a general (not FKBP10-selective) PPIase inhibitor, for
3 days (0.1–1 nM) resulted in a modest, but significant decrease
in L444P GC activity (Figure S4F) and a decrease in the total
GC band as well as the endo H sensitive GC band, without
significantly altering FKBP10 levels (Figure S4G). This contrasts
with the increase in GC proteostasis observed upon FKBP10
silencing. FK506 treatment (0.1 nM) enhanced the GC-FKBP10
interaction, as more GC was detected in the FKBP10
immunoprecipitates by western blot analysis (Figure 4C, IP
panels). Successive deletions of the PPIase domains from the
N-terminus of FKBP10 (Figure 4D) did not disrupt the interaction
between FLAG-tagged FKBP10 and VSVG-tagged WT GC
(Figure 4E), with the exception of the 375-582 construct wherein
all but one of the PPIase domains were deleted, suggesting
that a minimum of two PPIase domains are required for binding
to GC.Chemistry & Biology 20, 4We also scrutinized the role of Ca2+ in theGC-FKBP10 interac-
tion becausemouse FKBP9 has been shown to bind Ca2+ in vitro
(Shadidy et al., 1999). Chelating Ca2+ ions from the lysate prior to
immunoprecipitating FKBP10 revealed that the GC-FKBP10
interaction appeared to be Ca2+ independent (Figure 4F). Our
data suggest that FKBP10 directs misfolding-prone GC into
ERAD by associating with it in a manner that does not appear
to require FKBP10’s PPIase activity or Ca2+ binding.
FKBP10 Overexpression Accelerates the ERAD
of Mutant Glucocerebrosidase
To examine whether FKBP10 influenced the degradation versus
folding and trafficking decision, we employed pulse-chase ex-
periments, taking advantage of the fact that radiolabeled, endo
H treated, WT GC will afford both endo H resistant (reflecting
the rate of GC folding and trafficking; Figure S5A) and endo H
sensitive GC (reflecting the rate of GC degradation; Figure S5A)
bands (Jonsson et al., 1987; Schmitz et al., 2005). Upon FKBP10
silencing of WT GC fibroblasts, the rate of appearance of radio-
labeled endo H resistant WT GC was significantly faster in
comparison to the NT siRNA control (5-hr chase, Figure 5A),
possibly due to increased association of WT GC with calnexin
(see below). In contrast, there was no significant difference in
the rate of disappearance of radiolabeled endo H sensitive WT
GC between the FKBP10 siRNA and NT siRNA treated samples
over the same chase period (Figure 5B). When VSVG-WT
or -L444P GC and FKBP10-FLAG were co-overexpressed in
HeLa cells, the rates of WT and L444P GC degradation were
significantly faster with FKBP10 overexpression than with the
empty vector control after a 5-hr chase period (*p < 0.05) (Figures
5C and 5D). A GC immunoisolation revealed that FKBP10 bound
to newly synthesized WT and L444P GC at the outset of the
chase period (0 hr), and binding continued over a 5-hr chase
period, consistent with the notion that FKBP10 bound to and
enhanced ERAD of GC (Figures S5B and S5C).
FKBP10 May Collaborate with OS-9 to Deliver GC
for Degradation
To further explore the role of FKBP10, we investigated the
possible involvement of OS-9 in ERAD of GC. OS-9 is an
ERAD lectin that interacts with the membrane-embedded ubiq-
uitin ligase HRD1-SEL1L complex (Bernasconi et al., 2010;
Christianson et al., 2008). Current models posit that OS-9 can
recognize demannosylated oligosaccharides on glycoproteins
and/or the misfolded nonglycosylated structures of proteins,
resulting in ERAD of glycoproteins (Hebert et al., 2010). Co-over-
expressed FKBP10 and L444P GC co-immunoprecipitated in
HeLa cell lysates with endogenous OS-9 employing an OS-9
antibody (Figures 6A and 6B, respectively). Moreover, overex-
pressed OS-9 interacted with endogenous WT GC (Figure 6C)
and immunoprecipitating GC and OS-9 sequentially from the
HeLa cell lysates enabled the detection of FKBP10 (Figure S6A).
This suggested that ERAD of GC may involve the association of
GC with both FKBP10 and OS-9, possibly as a ternary complex.
An interaction between glycosylated FKBP10 and XTP3-B,
which can substitute for OS-9 (Bernasconi et al., 2010; Christian-
son et al., 2008), was not detected. Notably, silencing OS-9 in
GC fibroblasts increased L444PGC function 1.2- to 1.4-fold (Fig-
ure 6D, *p < 0.05), supporting the notion that OS-9 may be03–415, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 407
Figure 3. FKBP10 Is a GC Proteostasis Network Component
(A) Schematic representation of the domain structures of FKBP10, FKBP9, and FKBP2.
(B) Depleting the levels of FKBP10 (and FKBP9) significantly increases L444P, G202R, and WT GC activity in fibroblasts.
(C) Depleting the levels of FKBP10 and FKBP9 increases GC lysosomal trafficking in L444P GC fibroblasts.
(D) Depleting the levels of FKBP10 and FKBP9 increases the endo H-resistant GC glycoform in L444P andWT GC fibroblasts. Quantification of endo H-resistant
GC bands is shown on the right of (D).
(E) The FKBP10 overexpression significantly decreases WT and L444P GC activity in fibroblasts.
(legend continued on next page)
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Figure 4. FKBP10 Partitions GC to the ERAD Pathway, Independent of Its PPIase or Ca2+ Binding Activity
(A) Overexpressing FKBP10 or EDEM1 decreases the steady-state levels of VSVG-tagged GC in HeLa cells. Both FKBP10 and EDEM1 bind to GC.
(B) Inhibiting proteasomal degradation using lactacystin leads to more endogenous GC binding to overexpressed FKBP10.
(C) FK506 treatment modestly decreases GC levels and enhances the GC-FKBP10 interaction in HeLa cells.
(D) Schematic representation of the various FKBP10 truncations used in the immunoprecipitation experiment in (E).
(E) A minimum of two PPIase domains is required for FKBP10 to associate with WT GC.
(F) Chelating Ca2+ ions in the lysate using EGTA does not affect the GC-FKBP10 interaction. The experiments were done three times.
See also Figure S4.
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additivity in L444P GC activity when OS-9 and FKBP10 siRNA
were co-applied (Figure 6D, **p > 0.1) suggests that FKBP10
and OS-9 function in the same pathway for GC ERAD, possibly
through a direct interaction.(F) The GC-FKBP10 endogenous interaction is confirmed using ER fractions fro
analysis identified FKBP10 after immunoprecipitation of HeLa ER fractions using
The data in (B), (D) and (E) are reported as mean ± SEM (n = 8 for B and E) and
*p < 0.01.
See also Figure S3.
Chemistry & Biology 20, 4FKBP10 Competes with Calnexin for GC Binding Early
in the Progression of GC through the ER Proteostasis
Network
Calnexin binding toGCenables its productive folding and ER exit
(Ong et al., 2010). We hypothesized that FKBP10 and calnexinm HeLa cells or WT fibroblasts. Both western blot analysis and tandem MS
8E4 GC antibody. The experiments were done three times.
any statistical significance was calculated using a two-tailed Student’s t test.
03–415, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 409
Figure 5. The Level of FKBP10 Influences
the Degradation Rate of both WT and
L444P GC
(A) FKBP10 knockdown increases the rate of WT
GC folding and trafficking (as reflected by the endo
H-resistant GC band) in fibroblasts when
compared to the NT siRNA control.
(B) Quantification of the endo H-sensitive GC band
intensity upon FKBP10 knockdown.
(C and D) Overexpression of FKBP10 significantly
increases the rate of WT (C) and L444P GC (D)
degradation in HeLa cells compared to the empty
vector control. Quantification of the bands was
performed using ImageJ (NIH software). The
experiments were done three times.
The data are reported asmean ± SD (n > 5) and any
statistical significance was calculated using a
two-tailed Student’s t test. *p < 0.05.
See also Figure S5.
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resulting in a bias toward degradation or folding, respectively
(Figure 7). As such, more GC should be bound to calnexin
when FKBP10 concentrations are reduced. Indeed, fibroblast
lysates with silenced FKBP10 exhibited an increased amount
of calnexin associated with the immunoprecipitated WT and
L444P GC (Figure 6E).
It is possible that FKBP10could associate directlywith calnexin
to accelerate mutant GC degradation, blocking the profolding
calnexin-GC interaction. Immunoprecipitating overexpressed
FLAG-tagged FKBP10 from HeLa cell lysate revealed that
FKBP10 associated with calnexin (Figure S6B). However, in the
reciprocal calnexin immunoprecipitation, calnexin associated
only with unglycosylated FKBP10 (Figure S6B), which is not the
physiologically relevant form. Furthermore, treating HeLa cells
with castanospermine to inhibit the interaction between calnexin
and its glycosylated substrates did not increase FKBP10-medi-
ated L444P GC degradation rate when compared to the empty
vector control (Figure S6C, lanes 10–12 cf 7–9, and Figure S6D,
right). Therefore, it appears that calnexin is not required for
FKBP10’s function to promote GC degradation in the ER.
FKBP10 Influences the Proteostasis of other
Misfolding-Prone Proteins
FKBP10 knockdown (>80%; Figure 6F, right) increased P356R
a-mannosidase lysosomal activity 1.5-fold in a-mannosidosis
patient-derived fibroblasts (Figure 6F, *p < 0.05), demonstrating
that the proteostasis of other LSD-associated enzymes can also
be enhanced. Enhancing calnexin function by increasing ER410 Chemistry & Biology 20, 403–415, March 21, 2013 ª2013 Elsevier Ltd All rights reservedCa2+ levels also increased P356R a-man-
nosidase proteostasis (Mu et al., 2008a),
consistent with our hypothesis that
calnexin and FKBP10 compete for LSD-
associated enzymes undergoing matura-
tion (Figure 7).
We also examined the effect of FKBP10
overexpression on the null Hong Kong
variant of a1-antitrypsin (NHK) (Hirao
et al., 2006; Oda et al., 2003) and RI332
(a mutant of ribophorin I) (de Virgilio et al., 1998), established
ERADsubstrates. FKBP10overexpression decreased the steady
state levels ofNHK, but notRI332 (Figure 6G, left panels), although
FKBP10 co-immunoprecipitated fromHeLa cell lysateswith both
of these ERAD substrates (Figure 6G, right panels). Interestingly,
OS-9 is required for the degradation of NHK (Christianson et al.,
2008) and given that FKBP10 and OS-9 interact (Figures 6B–
6D), these data are consistent with FKBP10 enhancing degrada-
tion for a variety of misfolding-prone substrates. To assess
whether the FKBP10-substrate interaction is N-glycan depen-
dent, we co-expressed FKBP10 with non-glycosylated, mutant
NHK-QQQ (Hirao et al., 2006). FKBP10 co-immunoprecipitated
with NHK-QQQ and its overexpression reduced the steady state
levels of NHK-QQQ (Figure 6H), suggesting that FKBP10 does
not distinguish its substrates by N-glycan recognition.
DISCUSSION
Proteomic assessment of patient-derived LSD fibroblasts
treated with mechanistically distinct PRs (MG-132 or diltiazem)
led to the identification of FKBP10 as an LSD enzyme proteosta-
sis network component. FKBP10, when silenced, enhances GC
proteostasis. FKBP9 appears to play a similar ERAD partitioning
role, although we focused largely on FKBP10.
The data demonstrate that increased ER FKBP10 levels accel-
erated GC ERAD, apparently by collaborating with OS-9 (Fig-
ure 7). Since OS-9 has been shown to deliver ERAD substrates
to themembrane-embedded HRD1-SEL1L ubiquitin ligase com-
plex for ERAD (Bernasconi et al., 2010; Christianson et al., 2008),
Figure 6. The Level of FKBP10 Influences the Proteostasis of Other Substrates besides GC
(A and B) Overexpressed FKBP10 (A) and overexpressed L444P GC (B) co-immunoprecipitate with endogenous OS-9.
(C) Endogenous WT GC co-immunoprecipitates with overexpressed OS-9.
(D) The knockdown of OS-9, FKBP10 or the combination of OS-9 and FKBP10 in fibroblasts results in a similar increase in L444P GC activity (left). OS-9 and
FKBP10 are effectively depleted in the L444P GC fibroblasts (right).
(E) Silencing FKBP10 promotes the interaction between GC and calnexin.
(F) Depleting the FKBP10 level significantly increases P356R lysosomal a-mannosidase activity in patient-derived fibroblasts. FKBP10 is effectively depleted in
the fibroblasts (right).
(G) FKBP10 overexpression modestly decreases the steady state levels of NHK but not RI332 in HeLa cells. FKBP10 associates with both NHK and RI332.
(H) FKBP10 overexpression modestly decreases the steady state levels of NHK-QQQ in HeLa cells. FKBP10 associates with NHK-QQQ. The experiments were
done three times.
The data in (D) and (F) are reported as mean ± SD (n = 8) and any statistical significance was calculated using a two-tailed Student’s t test. *p < 0.05, **p > 0.1.
See also Figure S6.
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Figure 7. FKBP10 Serves as an ERAD
Partitioning Factor for Mutant Lysosomal
Enzymes
In the model, the newly synthesized unfolded
mutant lysosomal glycoenzyme encounters either
FKBP10 or calnexin in the ER, resulting in its deg-
radation or folding, respectively. FKBP10 bound-
lysosomal glycoenzyme appears to associate with
OS-9 that delivers misfolded lysosomal enzyme to
the ERAD machinery for cytosolic dislocation and
proteasome-mediated degradation. In the com-
petitive pathway, the calnexin bound-lysosomal
enzymes are folded into their native state, which
enables LIMP-2 (or an equivalent trafficking
receptor) binding and lysosomal trafficking.
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(GC-FKPB9) complex to HRD1-SEL1L to mediate ERAD.
Decreasing the concentration of FKBP10 appears to decrease
its competitiveness for misfolded GC, allowing profolding
components such as calnexin (levels increased by MG-132 or
diltiazem treatment) to more effectively compete for unfolded
glycosylated enzymes, resulting in their ER folding and exit
(Figure 7). The modest increases in mutant lysosomal GC or
P356R a-mannosidase activities observed with FKBP10 knock-
down are thought to be sufficient to ameliorate pathology in
patients (Schueler et al., 2004).
It appears that there is an early delicate balance between
calnexin-mediated glycoprotein folding versus FKBP 9- or
FKBP 10-mediated ERAD as lysosomal enzymes like GC begin
their journey through the ER proteostasis network. Generally
speaking, knocking down or inhibiting established ERAD pro-
teostasis network components does not lead to more folding,
trafficking and function of mutant LSD-associated enzymes
because they are too far along the ERAD pathway. That pertur-
bation of FKBP9 or FKBP10 can alter LSD mutant enzyme pro-
teostasis suggests that FKBP9 or FKBP10 makes an early
degradation versus folding decision before mannose trimming,
after which ERAD seems inevitable.
SIGNIFICANCE
In summary, silencing FKBP9 or FKBP10 enhances the
folding, trafficking, and lysosomal function of LSD-associ-
ated mutant enzymes to levels thought to be sufficient to
amelioratedisease.Thissuggests that thisapproach isworth
exploring as a LSD therapeutic strategy. Moreover, our data412 Chemistry & Biology 20, 403–415, March 21, 2013 ª2013 Elsevier Ltd All rights reservedreveals that a subset of FKBPs can
identify as yet unfolded proteins and
direct them to ERAD, suggesting that
some FKBPs act as ERAD partitioning
factors. As such, FKBP silencing could
be efficacious in other loss-of-function
diseases.
EXPERIMENTAL PROCEDURES
Reagents
Diltiazem hydrochloride was from Tocris Biosci-
ence (Ellisville, MO). MG-132 and lactacystin wasfrom Calbiochem (San Diego, CA). Four-methylumbelliferyl b-D-glucoside
(MUG), 4-methylumbelliferyl a-D-mannopyranoside, FK506 monohydrate,
castanospermine and EGTA were from Sigma (St. Louis, MO). Conduritol B
epoxide (CBE) and kifunensine were from Toronto Research Chemicals
(Downsview, ON, Canada). Cell culture media were purchased from GIBCO
(Grand Island, NY).
Cell Cultures
Primary skin fibroblast cultures were established from patients with Gaucher
disease homozygous for either the G202R GC (c.721G > A) mutation (kindly
provided by Dr. K.P. Zimmer [Children’s Hospital of the University of Munster,
Munster]) or the N370S GC (c.1226A > G) mutation (kindly provided by
Dr. E. Beutler). An apparently normal fibroblast cell line (GM00498), the
Gaucher disease fibroblast cell line homozygous for the L444P (c.1448T > C)
mutation (GM08760) and a homozygous a-mannosidosis fibroblast cell line
containing the P356R a-mannosidase mutation (GM04518) were obtained
from Coriell Cell Repositories (Camden, NJ). Fibroblasts were grown in
minimal essential medium with Earle’s salts supplemented with 10% heat-
inactivated fetal bovine serum and 1% glutamine Pen-Strep at 37C in 5%
CO2. Cell mediumwas replaced every 3 or 4 days. Monolayers were passaged
upon reaching confluency with TrypLE Express.
Relative Quantification of Protein Expression Level Changes
by MudPIT
Proteins from L444P GC fibroblasts treated with diltiazem (10 mM) for 5 d,
MG-132 (0.8 mM) for 3 days, or the respective vehicle controls were subjected
to MudPIT mass spectrometry proteomics analysis (Link et al., 1999;
Washburn et al., 2001). See Supplemental Experimental Procedures for
detailed method. Estimation of protein abundance based on spectral count
was used as the relative quantification method (Liu et al., 2004) which has
been widely applied (Cao et al., 2008; Liao et al., 2007; Rikova et al., 2007).
Spectral counts from the three replicates of each sample were merged to
average the run-to-run variation and a normalization factor (F = total number
of spectra in control sample/Total number of spectra in treated sample) was
applied. We used stringent, albeit arbitrary, criteria for the significantly altered
protein expression level after drug treatment. If a protein is detected in both
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filtered according to the following criteria: (1) if the same protein was identified
in both samples with spectra counts greater than 10, normalized spectra count
ratios of 2 or above were considered as increased; likewise, 0.5 or less as
decreased; (2) if the same protein was identified in both samples with a spectra
count from either of them less than 10 but the difference between the two was
greater than 10, normalized spectra count ratios of 2.5 or above were con-
sidered as increased; likewise, 0.4 or less as decreased. If a protein was iden-
tified in only one sample, a spectra count of greater than 20 was considered
a significant change. Details about the identified proteins are given in the
Supplemental Experimental Procedures and Table S1 (significant up- or down-
regulation) and Table S2 (functional characterization).
Enzyme Activity Assays
The intact cell GC activity and lysed cell GC activity assays for WT, L444P,
N370S, and G202R GC fibroblasts using the MUG substrate were described
previously (Mu et al., 2008b; Sawkar et al., 2002). The activity of lysosomal
a-mannosidase was determined as previously described with the minor
modification of using 2 mM 4-methylumbelliferyl a-D-mannopyranoside as
the substrate (Gotoda et al., 1998). Each data point reported was evaluated
at least in triplicate in each plate, and on three different days. See Supple-
mental Experimental Procedures for detailed method.
Western Blot Analysis
Cells were lysed with Roche complete lysis-M buffer containing complete
protease inhibitor cocktail. Company specifications were followed for protein
treatment with Endo H or PNGase F (New England Biolabs). Aliquots of cell
lysates were separated in a 10% SDS-PAGE gel and western blot analysis
was performed using appropriate antibodies. Details of antibodies used are
given in the Supplemental Experimental Procedures.
Immunofluorescence
Immunofluorescence was performed as previously described (Mu et al.,
2008b; Sawkar et al., 2006). The experiments were done three times and
similar results were obtained. See Supplemental Experimental Procedures
for detailed method.
Plasmid and siRNA Transfection
HeLa cells and patient-derived GC fibroblasts were seeded at approximately
23 105 cells per well in six-well plates and allowed to reach80% confluency
before transient transfection using Fugene 6 transfection reagent (Roche) for
plasmids or HiPerfect Transfection Reagent (QIAGEN) for siRNA, according
to themanufacturers’ instructions. Details of the plasmids and siRNA duplexes
used can be found in the Supplemental Experimental Procedures.
Quantitative RT-PCR
The relative expression levels of target genes were analyzed by quantitative
RT-PCR using the forward and reverse primers for the genes analyzed
as described previously (Mu et al., 2008a, 2008b; Ong et al., 2010). See
Supplemental Experimental Procedures for detailed method. Each data point
was evaluated in triplicate, and measured three times.
Pulse-Chase and Immunoprecipitation
WT GC fibroblasts treated with FKBP10 siRNA for 4 days were starved
for 45 min, metabolically labeled with 60 mCi of 35S EasyTag (Perkin-Elmer)
for 1 hr as previously described (Jonsson et al., 1987; Schmitz et al., 2005)
and chased for the indicated periods. HeLa cells 24-hr posttransfection
were starved for 45 min before being metabolically labeled for 15 min. See
Supplemental Experimental Procedures for detailed method.
Enrichment of the ER Fraction
Cells were collected, washed in PBS, and crosslinked using 1mMDSP (Pierce)
according to the manufacturer’s instructions. After undergoing three freeze-
thaw cycles, cells were lysed in lysis buffer (50 mM Tris, 150 mM NaCl,
pH 7.5) containing protease inhibitor cocktail (Roche). For enrichment of the
ER fraction, lysates were depleted of nuclei via centrifugation at 800 g for
10 min. The supernatant was then centrifuged at 10,000 g for 10 min to pellet
the mitochondria, and the supernatant was then ultracentrifuged at 100,000 gChemistry & Biology 20, 4for 65 min to pellet the ER. The ER pellet was resuspended in lysis buffer plus
1% Triton X-100 and Roche protease inhibitor cocktail. The ER protein
concentration was quantified using a microBCA assay (Pierce).
The Effect of Calcium on the FKBP10-GC Protein Interaction
Lysates were incubated with 2 mM EGTA for 15 min at 37C prior to the
addition of the mouse monoclonal anti-FLAG antibody for immunoprecipita-
tion as described previously (Le et al., 1994; Ong et al., 2010).
The Effect of FK506 on the FKBP10-GC Interaction
HeLa cells 24 hr posttransfection were treated with FK506 (0.1 nM) for 24 hr.
The mouse monoclonal anti-FLAG antibody was added to the lysates prior
to immunoprecipitation.
The Effect of Proteasomal Degradation on the FKBP10-GC
Interaction
HeLa cells 24 hr posttransfection were treated with lactacystin (5 mM) for 24 hr
prior to lysis. The lysates were subjected to immunoprecipitation with the
mouse monoclonal anti-FLAG antibody.
Sequential Immunoprecipitation of GC and OS-9
GC proteins were immunoprecipitated from HeLa cells 48 hr posttransfection
using the anti-VSVG antibody and the bound proteins were eluted using VSVG
peptides (Roche) at 37C for 30 min. The eluted proteins were subjected to
a second round of immunoprecipitation using the anti-OS-9 antibody and
the resulting bound proteins were eluted by boiling in SDS loading buffer in
the presence of DTT.
Statistical Analysis
All data are presented as mean ± SEM or mean ± SD as stated and any statis-
tical significance was calculated using two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chembiol.2012.11.014.
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